article thumbnail

Drug Manufacturers’ 340B Restrictions Generate New Round Of Media Scrutiny & Criticism

Proxsys Rx

After all, as reported in a March, 2021 Fact Sheet published by the American Hospital Association , the total value of the 340B program amounts to just 5% of the U.S. Irrespective of insurance status, no patient pays retail drug prices. million people will become uninsured after losing Medicaid coverage. drug market.

article thumbnail

External control arms and debunking real-world data myths

pharmaphorum

Still, in 2021, we have seen the industry evolve and develop strategies on how to establish a viable ECA. We have seen some select examples of this across the industry, but in order to get to state where there is more widespread application of them, a more systematic approach to ECAs must be embedded into the overall development process.

article thumbnail

Top Performing Drug – Trikafta/Kaftrio (May Edition)

PharmaShots

In 2022, Vertex Pharma’s net product revenue spiked by 18%, vs. 2021, mainly due to influx of Trikafta in multiple countries internationally and the growing performance of Trikafta in the U.S. Limited Coverage: Insurance coverage and reimbursement policies may vary, leading to potential barriers for some patients in accessing Trikafta.